Twist Bioscience Corporation
Twist Bioscience Corporation (TWST) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · TWST · as of Sep 30, 2025
Ownership Breakdown
242
Institutional Holders
▼ 6 vs Q2
$2.08B
Total Inst. Value
▼ $540.64M vs Q2
62.27M
Shares Outstanding
freeFloat 95.69%
73.79M
13F Shares Held
▲ 2.65M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
TWST largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ARK INVESTMENT MANAGEMENT LLC biological products, (no diagnostic substances) | 6.73M | 11.21% | 11.21% | $189.29B | Nov 12, 2025 | ▲ 326.4K |
ARTISAN PARTNERS LIMITED PARTNERSHIP biological products, (no diagnostic substances) | 6.41M | 10.69% | 10.69% | $180.40B | Nov 12, 2025 | ▲ 1.35M |
BLACKROCK, INC. biological products, (no diagnostic substances) | 6.18M | 10.30% | 10.30% | $173.86B | Nov 12, 2025 | ▼ 98.1K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 5.77M | 9.61% | 9.61% | $162.32B | Nov 7, 2025 | ▼ 63.2K |
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC biological products, (no diagnostic substances) | 4.14M | 6.90% | 6.90% | $116.56B | Nov 12, 2025 | ▲ 235.7K |
EDGEPOINT INVESTMENT GROUP INC. biological products, (no diagnostic substances) | 4.08M | 6.80% | 6.80% | $114.88B | Nov 14, 2025 | ▲ 1.70M |
STATE STREET CORP biological products, (no diagnostic substances) | 3.09M | 5.15% | 5.15% | $86.93B | Nov 14, 2025 | ▲ 588.1K |
SUMITOMO MITSUI TRUST HOLDINGS, INC. biological products, (no diagnostic substances) | 2.12M | 3.53% | 3.53% | $59.66B | Oct 27, 2025 | ▼ 179.2K |
NIKKO ASSET MANAGEMENT AMERICAS, INC. biological products, (no diagnostic substances) | 2.12M | 3.53% | 3.53% | $59.64B | Nov 12, 2025 | ▼ 179.2K |
SOLEUS CAPITAL MANAGEMENT, L.P. biological products, (no diagnostic substances) | 1.87M | 3.11% | 3.11% | $52.52B | Nov 14, 2025 | ▲ 1.51M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
33
Increased
+9.91M shares0
New Positions
first time holders16
Decreased
−4.20M shares0
Sold Out
fully exitedNet shares change (top 50)
+5.71M
+9.91M / −4.20M
Net new holders
+17
0 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
TWST insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
10
Buy transactions
27
Sell transactions
0.37
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Cho Dennis See Remarks | May 29, 2026 | Sale | 14,205 | $69.75 | $990.8K | 120.1K | Form 4 ↗ |
Laponis Adam Chief Financial Officer | May 29, 2026 | Sale | 4,000 | $70.00 | $280.0K | 112.7K | Form 4 ↗ |
Leproust Emily M. Chief Executive Officer | May 28, 2026 | Sale | 1,482 | $65.33 | $96.8K | 861.9K | Form 4 ↗ |
Leproust Emily M. Chief Executive Officer | May 28, 2026 | Sale | 900 | $66.85 | $60.2K | 861.0K | Form 4 ↗ |
Leproust Emily M. Chief Executive Officer | May 28, 2026 | Sale | 7,623 | $67.95 | $518.0K | 853.3K | Form 4 ↗ |
Leproust Emily M. Chief Executive Officer | May 28, 2026 | Sale | 6,465 | $68.61 | $443.6K | 846.9K | Form 4 ↗ |
Starovasnik Melissa A. director | May 28, 2026 | Sale | 2,500 | $68.00 | $170.0K | 22.2K | Form 4 ↗ |
Starovasnik Melissa A. director | May 26, 2026 | Sale | 500 | $61.04 | $30.5K | 24.7K | Form 4 ↗ |
Leproust Emily M. Chief Executive Officer | May 27, 2026 | Sale | 23,752 | $65.24 | $1.55M | 848.1K | Form 4 ↗ |
Leproust Emily M. Chief Executive Officer | May 26, 2026 | Sale | 24,282 | $65.08 | $1.58M | 846.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Twist Bioscience Corporation (TWST) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 4.31%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Twist Bioscience Corporation is ARK INVESTMENT MANAGEMENT LLC, holding approximately 6.73 million shares — equal to 11.21% of outstanding shares — as of September 30, 2025.
A total of 242 institutional investors currently hold TWST stock, with a combined institutional value of approximately $2.08 billion as of the most recent 13F filing period.
Frequently asked questions
TWST ownershipTwist Bioscience Corporation (TWST) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is ARK INVESTMENT MANAGEMENT LLC with a 11.21% stake. Company insiders hold 4.31%. Data sourced from SEC Form 13F as of September 30, 2025.